Dendreon Announces Collaboration with The R.W. Johnson Pharmaceutical Research
Institute
in Development of Immunotherapy for Cancer
Business Editors/Health & Medical Writers
SEATTLE--(BW HealthWire)--Oct. 11, 2000--
leader in cancer vaccines to advance
research and development activities
Dendreon Corporation (Nasdaq:DNDN) today announced the signing of
a strategic collaboration agreement for the advancement of cancer
immunotherapies with The R.W. Johnson Pharmaceutical Research
Institute (PRI), a member of the Johnson & Johnson family of companies
(NYSE:JNJ).
The collaboration will provide the opportunity for Dendreon and
PRI to use each other's products and technologies to develop optimal
immunotherapies, including dendritic cell-based vaccine therapy for
the treatment of a variety of cancers, including breast, ovarian and
colorectal cancers. The collaboration will also involve the use of
products and technologies that may be developed by the companies.
"PRI is a strong partner for Dendreon Corporation," said David
Urdal, Ph.D., Chief Scientific Officer of Dendreon. "PRI's innovation
in biotechnology, coupled with Dendreon's leadership in the cancer
immunotherapy arena, provides a significant validation for this
important area of clinical development and a strong groundwork for our
future research and development activities."
Under the terms of the agreement, PRI will provide financial
support for research and development activities to be carried out by
Dendreon. Dendreon will also be responsible for clinical testing.
Immunotherapy treatments aim to harness the natural power of the
immune system to fight against diseases such as cancer. Avoiding the
harsh side effects associated with other forms of treatment,
immunotherapies may offer new hope to patients.
Dendreon Corporation (www.dendreon.com) is dedicated to the
discovery and development of novel products for the treatment of
cancer through its innovative manipulation of the immune system.
Dendreon is focused on the development of therapeutic cancer vaccines
through the use of antigen discovery, antigen engineering and
dendritic cell technologies. Dendreon's vaccine for the treatment of
prostate cancer, Provenge(TM), is in Phase III clinical trials and its
vaccine for the treatment of multiple myeloma, Mylovenge(TM), is in
Phase II clinical trials.
Except for historical information contained herein, this news
release contains forward-looking statements that are subject to risks
and uncertainties that may cause actual results to differ materially
from the results discussed in the forward-looking statements,
particularly those inherent in the process of discovering, developing
and commercializing drugs that are safe and effective for use as human
therapeutics. Factors that may cause such a difference include risks
related to Dendreon's limited operating history, risks associated with
completing our clinical trials, and dependence on the efforts of third
parties, and our dependence on intellectual property. Further
information on the factors and risks that could affect Dendreon's
business, financial condition and results of operations, are contained
in Dendreon's SEC Reports, including Dendreon's Form 10-Q and Form S-1
Registration Statement, No. 333-31920, which are available at
www.sec.gov.
--30--AMP/se*
CONTACT: Dendreon Corporation
Julie Rathbun, 206/256-4545 ext. 1500
jrathbun@dendreon.com |
